MeSH term
Frequency | Condition_Probility | Adult | 16 | 0.0 |
Humans | 55 | 0.0 |
Male | 37 | 0.0 |
Middle Aged | 32 | 0.0 |
Reference Values | 2 | 0.0 |
Risk Factors | 3 | 0.0 |
Aged | 25 | 0.0 |
Apoptosis/physiology | 2 | 0.0 |
Disease-Free Survival | 2 | 0.0 |
Female | 37 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Liver/pathology | 3 | 1.0 |
Prognosis | 8 | 0.0 |
Survival Analysis | 3 | 0.0 |
Loss of Heterozygosity | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 26 | 0.0 |
alpha-Fetoproteins/*metabolism | 2 | 1.0 |
Aged, 80 and over | 7 | 0.0 |
Carcinoma, Hepatocellular/*metabolism/pathology | 3 | 4.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Liver Neoplasms/*metabolism/pathology | 3 | 4.0 |
Diagnosis, Differential | 2 | 0.0 |
Animals | 8 | 0.0 |
Blotting, Northern | 2 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Mice | 5 | 0.0 |
Molecular Sequence Data | 6 | 0.0 |
Phenotype | 2 | 0.0 |
X Chromosome/*genetics | 2 | 0.0 |
Gene Expression | 4 | 0.0 |
Immunohistochemistry | 9 | 0.0 |
Carcinoma, Hepatocellular/*pathology | 2 | 4.0 |
Comparative Study | 6 | 0.0 |
Liver/*pathology | 2 | 3.0 |
Liver Neoplasms/*pathology | 3 | 5.0 |
Microsatellite Repeats | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 8 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Adolescent | 2 | 0.0 |
Child | 2 | 0.0 |
Disease Progression | 2 | 0.0 |
Follow-Up Studies | 3 | 0.0 |
Survival Rate | 4 | 0.0 |
Transcription, Genetic | 4 | 0.0 |
Protein Binding | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 4 | 0.0 |
Amino Acid Sequence | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Liver/enzymology | 2 | 0.0 |
Liver Neoplasms/*enzymology | 2 | 8.0 |
Sensitivity and Specificity | 2 | 0.0 |
Cell Line | 2 | 0.0 |
RNA, Messenger/metabolism | 4 | 0.0 |
*Genes, p53 | 2 | 0.0 |
Mutation | 2 | 0.0 |
Base Sequence | 5 | 0.0 |
*X Chromosome | 2 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Hepatectomy | 2 | 2.0 |
Carcinoma, Hepatocellular/*genetics | 2 | 2.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Transfection | 3 | 0.0 |
Tumor Cells, Cultured | 3 | 0.0 |
*DNA Methylation | 2 | 0.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Ethanol/*administration & dosage | 3 | 17.0 |
Injections, Intralesional | 2 | 4.0 |
English Abstract | 2 | 0.0 |
alpha-Fetoproteins/analysis | 3 | 1.0 |
Biopsy, Needle | 2 | 0.0 |
Time Factors | 3 | 0.0 |
Hepatitis B Surface Antigens/analysis | 2 | 3.0 |
Neoplasm Recurrence, Local | 2 | 0.0 |
Staining and Labeling | 2 | 0.0 |
DNA Methylation | 2 | 0.0 |
Adenoviridae/genetics | 2 | 0.0 |
